103440-75-1 Usage
Description
4H-1-Benzopyran-4-one, 7-amino-2,3-dihydrois a chemical compound with the molecular formula C10H11NO2. It is a derivative of 4H-1-benzopyran-4-one, a heterocyclic compound that consists of a pyran ring fused to a benzene ring. 4H-1-BENZOPYRAN-4-ONE, 7-AMINO-2,3-DIHYDROcontains an amino group and a dihydro moiety, which are important functional groups in organic chemistry. Its unique structure and reactivity may have various applications in pharmaceuticals, agrochemicals, and other organic synthesis processes.
Used in Pharmaceutical Industry:
4H-1-Benzopyran-4-one, 7-amino-2,3-dihydrois used as a pharmaceutical intermediate for the synthesis of various drugs and drug candidates. Its unique structure and reactivity make it a promising candidate for the development of new therapeutic agents.
Used in Agrochemical Industry:
4H-1-Benzopyran-4-one, 7-amino-2,3-dihydrois used as an agrochemical intermediate for the synthesis of various pesticides and agrochemical products. Its unique structure and reactivity can contribute to the development of new and effective agrochemicals.
Used in Organic Synthesis:
4H-1-Benzopyran-4-one, 7-amino-2,3-dihydrois used as a key intermediate in various organic synthesis processes. Its unique structure and reactivity make it a valuable building block for the synthesis of complex organic molecules and compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 103440-75-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,4,4 and 0 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 103440-75:
(8*1)+(7*0)+(6*3)+(5*4)+(4*4)+(3*0)+(2*7)+(1*5)=81
81 % 10 = 1
So 103440-75-1 is a valid CAS Registry Number.
103440-75-1Relevant articles and documents
TYK2 INHIBITORS AND USES THEREOF
-
, (2016/09/26)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.